Are we ready to use TMB in breast cancer clinical practice?

Research output: Contribution to journalEditorialpeer-review


We discussed the potentialities of tumor mutation burden (TMB) as a predictive marker for immunotherapy in breast cancer, also highlighting the limits that have hindered its introduction in the clinical practice. Although some studies have demonstrated the possibility to select patients more responsive to immune-checkpoint inhibitors by evaluating TMB, some issues emerged regarding the complexity of the methodologies for its determination, the costs of the analysis, and the necessity to improve the TMB determination with that of neoantigen identification.

Original languageEnglish
Pages (from-to)1943-1945
Number of pages3
JournalCancer Immunology, Immunotherapy
Issue number10
Publication statusPublished - Oct 1 2020


  • Breast cancer
  • Immune-checkpoint inhibitors
  • PD-L1
  • TMB

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Are we ready to use TMB in breast cancer clinical practice?'. Together they form a unique fingerprint.

Cite this